Sequencing of bio-banked samples to identify molecular drivers in an early-phase clinical trial
Sequencing to support patient eligibility screening and molecular characterization of patients enrolled across later phase trial under a significant risk IDE
Analytical and clinical validation of multiple biomarkers under a NGS assay for pursuit of a companion diagnostic partnership
Testing specific cohorts of patients to identify appropriate patients for targeted therapies in rare patient populations
Our AI-powered drug discovery and development platform uses machine learning and other advanced techniques to accelerate the discovery of new treatments.
Arrant is uniquely positioned with direct access to patients and bio-banked bio-specimens, whether its a retrospective study or requires longitudinal follow up of patients we can deliver the results for clients at speed and scale.